Josh Mandel-Brehm

CIK: 0001927058

Transaction Breakdown

Open Market Buys (P)2 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (70.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (10.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CAMP

Camp4 Therapeutics Corp

DirectorOfficer

PMN

ProMIS Neurosciences Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

CAMP
Camp4 Therapeutics Corp
Aug 3, 2026
Purchase(P)
Direct
6.6K shares at avg. $1.65$11K
PMN
ProMIS Neurosciences Inc.
May 20, 2026
Award(A)
Option (right to buy)
Direct
11K shares-
PMN
ProMIS Neurosciences Inc.
May 20, 2026
Award(A)
Option (right to buy)
Direct
5.5K shares-
CAMP
Camp4 Therapeutics Corp
Apr 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
580K shares-
CAMP
Camp4 Therapeutics Corp
Dec 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
425K shares-
CAMP
Camp4 Therapeutics Corp
Sep 11, 2025
Purchase(P)
Direct
6.1K shares at avg. $1.65$10K
PMN
ProMIS Neurosciences Inc.
Jun 12, 2025
Award(A)
Option (right to buy)
Direct
20K shares-
CAMP
Camp4 Therapeutics Corp
Apr 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
160K shares-
CAMP
Camp4 Therapeutics Corp
Oct 15, 2024
Conversion(C)
Direct
605 shares-
PMN
ProMIS Neurosciences Inc.
Oct 3, 2024
Award(A)
Option (right to buy)
Direct
40K shares-

		Type	Shares	Price		Ownership
Aug 3, 2026	CAMP Camp4 Therapeutics Corp	Purchase(P)	6,551	$1.65	$10,809	Direct
May 20, 2026	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	11,000	-	-	Direct
May 20, 2026	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	5,500	-	-	Direct
Apr 1, 2026	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	580,000	-	-	Direct
Dec 11, 2025	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	425,000	-	-	Direct
Sep 11, 2025	CAMP Camp4 Therapeutics Corp	Purchase(P)	6,060	$1.65	$9,999	Direct
Jun 12, 2025	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	20,000	-	-	Direct
Apr 1, 2025	CAMP Camp4 Therapeutics Corp	Award(A) Stock Option (Right to Buy)	160,000	-	-	Direct
Oct 15, 2024	CAMP Camp4 Therapeutics Corp	Conversion(C)	605	-	$0	Direct
Oct 3, 2024	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	40,000	-	-	Direct

1-10 of 10 transactions

About Mandel-Brehm Josh

Mandel-Brehm Josh (SEC CIK 0001927058) files insider reports with the SEC as Chief Executive Officer of Camp4 Therapeutics Corp (CAMP) and Director of ProMIS Neurosciences Inc. (PMN).

Signal8 holds 10 ownership filings by Mandel-Brehm Josh (1 Form 3, 9 Form 4), filed between Oct 7, 2024 and Aug 5, 2026. Those filings report 10 transactions, from Oct 3, 2024 to Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mandel-Brehm Josh's filings is in CAMBRIDGE, MA.

Recent filings by Mandel-Brehm Josh

Aug 3, 2026: Open-market purchase of CAMP shares (Form 4, code P).
May 20, 2026: Grants or awards of PMN derivative securities (2 lines, Form 4, code A).
Apr 1, 2026: Grant or award of CAMP derivative securities (Form 4, code A).
Dec 11, 2025: Grant or award of CAMP derivative securities (Form 4, code A).
Sep 11, 2025: Open-market purchase of CAMP shares (Form 4, code P).

Other insiders filing for Camp4 Therapeutics Corp (CAMP)

Gold Kelly, Chief Financial Officer
Schwab Andrew J., Director
Tardiff Daniel, Chief Scientific Officer
5AM Partners VI, LLC, 10% Owner
Young Richard A, Director
Maricich Yuri, Chief Medical Officer

How to read Form 4 transaction codes